Mauro G Mastropasqua
Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
Denkert C, Müller V, Klauschen F, Ataseven B, Engels K, Kammler R, Pfitzner B, Dietel M, Fasching P, Colleoni M, Blohmer J, Mehta K, Budczies J, Regan M, Loibl S, Dell'Orto P, von Minckwitz G, Mastropasqua M, Solbach C, Thürlimann B, Viale G. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Res Treat 2019; 176:557-568.
07.05.2019Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial
07.05.2019Breast Cancer Res Treat 2019; 176:557-568
Denkert Carsten, Müller Volkmar, Klauschen Frederick, Ataseven Beyhan, Engels Knut, Kammler Roswitha, Pfitzner Berit M, Dietel Manfred, Fasching Peter A, Colleoni Marco, Blohmer Jens-Uwe, Mehta Keyur, Budczies Jan, Regan Meredith M, Loibl Sibylle, Dell'Orto Patrizia, von Minckwitz Gunter, Mastropasqua Mauro G, Solbach Christine, Thürlimann Beat, Viale Giuseppe
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
Varga Z, Viale G, Mastropasqua M, Wagner U, Tapia C, Singer G, Schreiber-Facklam H, Schobinger-Clement S, Sancho Oliver S, Rakozy C, Padberg B, Öhlschlegel C, Obermann E, Noske A, Kaup D, Frick H, Dommann-Scherrer C, Diebold J, Lehr H. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PloS one 2012; 7:e37379.
25.05.2012How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists
25.05.2012PloS one 2012; 7:e37379
Varga Zsuzsanna, Viale Giuseppe, Mastropasqua Mauro G, Wagner Urs, Tapia Coya, Singer Gad, Schreiber-Facklam Heide, Schobinger-Clement Sylviane, Sancho Oliver Sara, Rakozy Christiane, Padberg Barbara, Öhlschlegel Christian, Obermann Ellen, Noske Aurelia, Kaup Daniela, Frick Harald, Dommann-Scherrer Corina, Diebold Joachim, Lehr Hans-Anton
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
Viale G, Olszewski W, Knox F, Thürlimann B, Price K, Castiglione-Gertsch M, Gelber R, Gusterson B, Goldhirsch A, Orosz Z, Neven P, Öhlschlegel C, Giobbie-Hurder A, Regan M, Coates A, Mastropasqua M, Dell'Orto P, Maiorano E, MacGrogan G, Braye S, Breast International Group Trial 1-98. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008; 26:5569-75.
03.11.2008Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole
03.11.2008J Clin Oncol 2008; 26:5569-75
Viale Giuseppe, Olszewski Wojciech P, Knox Fiona, Thürlimann Beat, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Gusterson Barry A, Goldhirsch Aron, Orosz Zsolt, Neven Patrick, Öhlschlegel Christian, Giobbie-Hurder Anita, Regan Meredith M, Coates Alan S, Mastropasqua Mauro G, Dell'Orto Patrizia, Maiorano Eugenio, MacGrogan Gaëtan, Braye Stephen G, Breast International Group Trial 1-98
Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Rusca T, Grigolato P, Braye S, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Mastropasqua M, Maiorano E, Regan M, Coates A. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. J Clin Oncol 2008; 26:1404-10.
20.03.2008Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
20.03.2008J Clin Oncol 2008; 26:1404-10
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Rusca Tiziana, Grigolato Piergiovanni, Braye Stephen, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown Robert W, Perin Tiziana, Golouh Rastko, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
Viale G, Coates A, Goldhirsch A, Gelber R, Castiglione-Gertsch M, Gusterson B, Öhlschlegel C, Pillay K, Kovács A, Brown R, Perin T, Golouh R, Price K, Colleoni M, Maiorano E, Maffini F, Mastropasqua M, Regan M, International Breast Cancer Study Group. Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst 2008; 100:207-12.
29.01.2008Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer
29.01.2008J Natl Cancer Inst 2008; 100:207-12
Viale Giuseppe, Coates Alan S, Goldhirsch Aron, Gelber Richard D, Castiglione-Gertsch Monica, Gusterson Barry A, Öhlschlegel Christian, Pillay Komala, Kovács Anikó, Brown R W, Perin Tiziana, Golouh Rastko, Price Karen N, Colleoni Marco, Maiorano Eugenio, Maffini Fausto, Mastropasqua Mauro G, Regan Meredith M, International Breast Cancer Study Group
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Rasmussen B, Altermatt H, Gelber R, Castiglione-Gertsch M, Goldhirsch A, Gusterson B, Thürlimann B, Coates A, Viale G, Braye S, Lacroix-Triki M, Regan M, Lykkesfeldt A, Dell'Orto P, Del Curto B, Henriksen K, Mastropasqua M, Price K, Méry E, BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. The Lancet 2008; 9:23-8.
01.01.2008Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
01.01.2008The Lancet 2008; 9:23-8
Rasmussen Birgitte B, Altermatt Hans J, Gelber Richard D, Castiglione-Gertsch Monica, Goldhirsch Aron, Gusterson Barry A, Thürlimann Beat, Coates Alan S, Viale Giuseppe, Braye Stephen, Lacroix-Triki Magali, Regan Meredith M, Lykkesfeldt Anne E, Dell'Orto Patrizia, Del Curto Barbara, Henriksen Katrine L, Mastropasqua Mauro G, Price Karen N, Méry Eliane, BIG 1-98 Collaborative and International Breast Cancer Study Groups
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
Viale G, Gusterson B, Goldhirsch A, Price K, Castiglione-Gertsch M, Gelber R, Thürlimann B, Öhlschlegel C, Braye S, Orosz Z, Neven P, Raffoul J, Rasmussen B, Dell'Orto P, Mastropasqua M, Maiorano E, Regan M, Coates A. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007; 25:3846-52.
06.08.2007Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
06.08.2007J Clin Oncol 2007; 25:3846-52
Viale Giuseppe, Gusterson Barry A, Goldhirsch Aron, Price Karen N, Castiglione-Gertsch Monica, Gelber Richard D, Thürlimann Beat, Öhlschlegel Christian, Braye Stephen, Orosz Zsolt, Neven Patrick, Raffoul Johnny, Rasmussen Birgitte Bruun, Dell'Orto Patrizia, Mastropasqua Mauro G, Maiorano Eugenio, Regan Meredith M, Coates Alan S